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ABSTRACT
Objective: To evaluate the usefulness of a third-generation PTH assay in the diagnosis of primary 
hyperparathyroidism (PHPT). Subjects and methods: Forty-one PHPT patients (4 men and 37 
women) with 61.2 ± 10.9 (mean ± SD) years, were studied and had PTH levels measured with two 
different methods using the same immunochemiluminescent assay plataform (Elecsys 2010 System, 
Roche). We compared a second-generation assay (I-PTH) with a third-generation PTH assay (Bio-PTH). 
Two populations of 423 and 120 healthy adults with serum 25OHD levels above 25 ng/mL were used 
to define normal values in the I-PTH and Bio-PTH assays respectively. Results: Normal PTH values 
based in the healthy adults population were 24.2-78.0 pg/mL for the I-PTH assay and 19.9-58.5 pg/mL 
for Bio-PTH assay. In PHPT patients, PTH values ranged from 67 to 553 pg/mL (median: 168 pg/mL) 
using the I-PTH assay and from 55 to 328 pg/mL (median: 111 pg/mL) using the Bio-PTH assay. Results 
obtained with the Bio-PTH assay were significantly lower (p < 0.0001, Wilcoxon). In general I-PTH and 
Bio-PTH showed highly significant correlation (r = 0.952, p < 0.0001). Passing–Bablok analysis gave a 
regression equation of Bio PTH = 13.44 + 0.59 x intact PTH. PHPT patients had 25OHD levels ranging 
from 4 to 36 ng/mL (mean 16.2 ng/mL); 35 subjects (85.3%) had values bellow 25 ng/mL. Conclusion: 
Our results demonstrate that both second and third generation PTH methods are strongly correlated 
in PHPT patients and control subjects. Lower results with Bio-PTH tests are expected in function of the 
assay specificity determined by the amino-terminal antibody used. Arch Endocrinol Metab. 2016;60(5):420-5
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INTRODUCTION
P arathyroid hormone (PTH) is an 84-amino-acid peptide produced exclusively by the parathyroid 
glands with a major role in regulating serum levels of 
calcium (1). Biochemically, this peptide contains two 
main portions, one carboxyl-terminal (COOH) and 
one amino-terminal (NH2). The classic biological 
activity of PTH, mediated by its receptor (type 1 PTH 
receptor, PTHR1), is dependent on the presence of an 
intact amino-terminal sequence, including the first four 
amino acids (2,3). After PTH is synthesized, it is stored 
in vesicles and partially metabolized within the cells. In 
this process, amino-terminal fragments are degraded, 
and carboxyl-terminal fragments are secreted along 
with intact molecules (PTH 1–84). These latter forms 
are quickly metabolized in the liver and have a half-
life of fewer than 4 minutes. The carboxyl-terminal 
fragments are eliminated by glomerular filtration and 
have a longer half-life in the circulation, although 
their biological effects are not completely known 
(4,5). These fragments have an activity potentially 
independent from their binding to the PTHR1 
receptor which, according to some studies, can result 
in hypocalcemia, hypophosphatemia, and increase 
in urinary phosphorus (6). Thus, circulating forms 
of PTH are quite heterogeneous and, considering 
that immunoassays depend on sequences recognized 
by antibodies, measurement of the so-called intact 
molecule (PTH 1-84) becomes a challenge (4).
The first radioimmunoassay (RIA) for human PTH 
was described by Berson and cols. in 1963 and, since 
then, several different assays have emerged (3,7). 
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The first RIA used polyclonal antibodies generated 
against PTH from bovine or porcine parathyroid 
glands, with specificity mainly directed against the 
carboxyl-terminal region (4,8). They were also called 
first-generation assays, and their major limitation was 
interference from PTH carboxyl fragments, especially 
in patients with impaired renal function (8). These 
characteristics imposed on these assays low sensitivity 
and specificity rates, in addition to significantly different 
results obtained with these first-generation methods (3).
Immunometric assays were introduced in the late 
1980s. These second-generation assays were based 
on the binding of two distinct antibodies, one against 
the amino-terminal segment and another against the 
carboxyl-terminal portion of the PTH, simplifying the 
diagnostic process (9). However, the ability of second-
generation assays to measure the intact PTH 1–84 form 
alone has been questioned after human studies showed 
the existence of long carboxyl-terminal fragments with 
a partial deletion of the first amino acids in the amino-
terminal portion, such as the form 7–84 (10-12). Thus, 
levels of biologically active PTH could be overestimated 
when measured by second-generation assays, since 
these long fragments are recognized by these assays 
even though they do not activate the PTHR1 (12). 
Third-generation immunometric assays (Bio-
PTH) have been developed in an attempt to identify 
exclusively the biologically active PTH (1–84) form. 
An amino-terminal specific antibody directed to the 
first four amino acids is used in third-generation assays 
to restrict the measurement to active molecular forms 
(1–84), not recognizing, therefore, long carboxyl-
terminal fragments (3,9).
Primary hyperparathyroidism is the third most 
common endocrine disorder, with an asymptomatic 
presentation in most cases (13). Measurement 
of serum PTH levels is crucial in establishing the 
diagnosis of primary hyperparathyroidism, although 
the measurement may be normal or inconclusive 
in some patients (14). To make matters worse, 
primary hyperparathyroidism may also present as a 
normocalcemic disease (15). Considering these factors, 
we conducted this study to evaluate the contribution of 
a third-generation assay in improving the diagnosis of 
primary hyperparathyroidism.
SUBJECTS AND METHODS
We studied 41 patients with primary 
hyperparathyroidism, followed up at the Metabolic 
Bone Diseases Unit of a teaching hospital at Escola 
Paulista de Medicina (Unifesp). The diagnosis of 
primary hyperparathyroidism had been confirmed by 
an elevated concentration of serum calcium measured 
at least twice, and intact PTH levels above the upper 
normal limit or inappropriately high using a second-
generation assay (I-PTH, Elecsys 2010 System, Roche), 
which is the standard method used at our center. Blood 
samples were collected after an overnight fast and 
aliquots were instantly frozen at -70oC. Serum calcium, 
phosphorus, albumin, and creatinine were measured 
by standard chemistry. Serum 25-hydroxyvitamin D 
[25(OH)D] was measured by chemiluminescence 
using the Liaison® (CLIA) assay.
All subjects had biochemical data consistent with 
the disease and were symptomatic or meeting at least 
one criteria for parathyroidectomy according to gui-
delines for the management of asymptomatic primary 
hyperparathyroidism from the Fourth International 
Workshop (16). Among these subjects, 29 underwent 
subsequent parathyroidectomy until the end of the 
study. Pathological analyses of their surgical specimens 
revealed that 25 of these patients had adenomas and 
four had parathyroid hyperplasia. Creatinine clearance, 
estimated with the Cockcroft-Gault equation (17), was 
above 60 mL/min in all patients. We measured PTH 
levels in the entire cohort with a second-generation 
(I-PTH) and a third-generation assay (Bio-PTH) using 
the same blood sample. Both measurements were per-
formed in the same immunochemiluminescent assay 
platform (Elecsys 2010 System, Roche). We used in 
both assays a capture antibody specific to the carbo-
xyl-terminal section, around amino acids 37–42. Two 
distinct amino-terminal antibodies were used for each 
assay, each one binding at two different antigenic sites: 
the 26–32 portion in the I-PTH assay and the 1–6 re-
gion in the Bio-PTH assay. 
Two groups of normal adults living in the city of 
São Paulo, one with 423 individuals and another with 
120, were used as controls to estimate normal PTH 
values measured with the I-PTH and Bio-PTH assays, 
respectively. All subjects in these groups had 25(OH)
D levels above 25 ng/mL and normal calcium levels.
Statistical analysis
For statistical analyses, we used the software GraphPad 
Prism, version 5 (GraphPad Software, Inc., La Jolla, CA, 
USA) or MedCalc, version 12 (Medcalc Software bvba, 
Mariakerke, Belgium). Data are expressed as mean and 
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standard deviation (SD), and 95% confidence interval 
(CI) for normally-distributed data, or as median and 
range for non-normally distributed data. The agreement 
between assays was assessed using Passing-Bablok 
regression and Bland-Altman analysis. Correlation was 
performed using Pearson’s correlation coefficient. The 
results were considered significant when their p values 
were < 0.05.
RESULTS
The mean age of the 41 patients with primary 
hyperparathyroidism enrolled in the study was 61.2 ± 
10.9 years, and 37 were women. Serum PTH levels in 
the control group varied from 24.2–78.0 pg/mL when 
measured with the I-PTH assay and 19.9–58.5 pg/mL 
when measured with the Bio-PTH assay. The biological 
data of the patients with primary hyperparathyroidism 
are shown in Table 1. 
Table 1. Biological data of 41 patients with primary hyperparathyroidism
Variable Mean ± SD Normal range
Age (years) 61.2 ± 10.9 N/A
25-OHD (ng/mL) 16.2 ±  7.2 30-60 ng/mL
Serum calcium (mg/dL) 11.6 ± 0.9 8.6-10.2
Ionized calcium (mmol/L) 1.61 ± 0.15 1.24-1.41
Serum phosphorus (mg/dL) 2.6 ± 0.4 2.5-4.5
Serum creatinine (mg/dL) 0.9 ± 0.3 0.5-1.2
SD: standard deviation; N/A: not available; 25(OH)D: 25-hydroxyvitamin D.
In patients with primary hyperparathyroidism, the 
mean serum concentration of calcium was 11.6 ± 0.9 
mg/dL (normal range 8.6–10.2 mg/dL) and that of 
ionized calcium was 1.61 ± 0.15 mmol/L (normal 
range 1.24–1.41 mmol/L). PTH values ranged from 67 
to 553 pg/mL (median 168 pg/mL) when measured 
with the intact assay (I-PTH) and from 55 to 328 pg/
mL (median 111 pg/mL) when measured with the 
Bio-PTH assay. Levels of 25(OH)D in patients with 
primary hyperparathyroidism ranged from 4 to 36 
ng/mL (mean 16.2 ng/mL) and in 35 of the 41 
subjects (85.3%), the levels were below 25 ng/mL.
Among patients with primary hyperparathyroidism, 
serum PTH levels were elevated in 36 (87.8%) when 
measured with the I-PTH assay and in 38 (92.7%) 
when measured with the Bio-PTH assay. All subjects 
with normal PTH levels by both assays had other causes 
of hypercalcemia excluded.
Figure 1. Correlation between serum Bio-PTH versus I-PTH in patients 
with primary hyperparathyroidism.
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Figure 2. Bland-Altman plot of the ratio of PTH levels obtained with the 
I-PTH and Bio-PTH assays (I-PTH/Bio-PTH ratio) against the average PTH 
level obtained with both methods. The bias ± 2 standard deviations (SD) 
between the methods was 1.5 ± 0.27.
Regression analysis showed that I-PTH and Bio-
PTH were highly correlated (r = 0.952, p < 0.0001) 
(Figure 1). However, the Passing-Bablok analysis 
resulted in the regression equation Bio-PTH = 13.44 
+ 0.59 x intact PTH. The 95%CI of the slope did not 
include 1 (95% CI 0.55–0.66), and that of the intercept 
did not include 0 (95% CI 2.08–20.0), indicating 
the presence of a proportional and systematic error. 
A Bland-Altman plotting also demonstrated poor 
agreement between the methods, with an increasing 
difference within the higher range of measurements 
(Figure 2). 
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Final numeric values obtained with the Bio-PTH assay 
were significantly lower than those obtained with the 
I-PTH assay (p < 0.0001, Wilcoxon), although one 
patient had a lower PTH value when measured by I-PTH 
compared with the value measured with Bio-PTH.
DISCUSSION
Primary hyperparathyroidism is a common endocrine 
disease. Over the past decades, the disease has shown 
a change in presentation at diagnosis, from very 
symptomatic to oligo- or asymptomatic, even in 
developing countries (13,18). These patients, who 
present with mild primary hyperparathyroidism, are less 
likely to show abnormal laboratory findings at diagnosis, 
and present serum calcium and PTH measurements 
not as elevated as patients with overt symptoms of the 
disease (19).
The introduction of second-generation assays 
has improved the quality of PTH measurement in all 
conditions associated with changes in this hormone’s 
levels. However, with an accumulation of data in the 
past years, the use of second-generation assays has 
shown some limitations (2). Since this assay recognizes 
PTH using two different antibodies, it is supposed 
to measure only whole PTH (1–84), the form that 
is capable of binding and activating the PTHR1 
(3,9,12). Amino-terminal antibodies generally used 
in this assay target the most antigenic portion of the 
amino nucleus, which lies between amino acids 15–
26 (9). However, Amour’s and cols. were the first to 
demonstrate the existence of long PTH fragments, 
such as PTH (7–84), that may be identified by second-
generation assays since only the first amino acid in 
the molecule is missing (10). The occurrence of these 
long PTH fragments is probably frequent, mainly in 
patients with kidney diseases due to their decreased 
glomerular filtration rate. Their occurrence has also 
been described in healthy individuals and patients 
with primary hyperparathyroidism (1,9). Previous 
studies have suggested increased PTH degradation 
within the glands in the presence of hypercalcemia and, 
consequently, a higher proportion of PTH fragments 
in the circulation (8,9). However, this phenomenon 
is not clinically important in patients with primary 
hyperparathyroidism. Brossard and cols. have compared 
the response to calcium infusion in healthy individuals 
and patients with hyperparathyroidism and found no 
significant difference in levels of carboxyl-terminal 
fragments between these two groups (20).
Due to the strict identification of PTH 1–84 and 
no measurement of its fragments, the absolute value of 
PTH measured with a third-generation assay is expected 
to be lower than that with a second-generation assay 
(9). This correlates with our findings in the current 
study. The use of a specific antibody targeting the 
first amino acid of the molecule prevents fragmented 
forms from interfering in the measurement (21). The 
ratio of third- to second-generation assays for PTH 
is usually < 1 in primary hyperparathyroidism, but in 
rare cases, the serum concentration of PTH measured 
with a third-generation assay may be higher than that 
measured with a second-generation assay, yielding a 
> 1 ratio (21,22). A possible explanation is that these 
patients may produce forms of PTH molecules that 
are not detected by second-generation assays and are 
possibly recognized by third-generation ones. Amour 
and cols. recently described an amino PTH (N-PTH), 
a molecule with preservation of the four first amino 
acids, therefore, recognizable by third-generation 
assays. However, N-PTH presents changes in the 
portion between amino acids 15–20 that prevents 
its recognition by second-generation assays (10,14). 
The main hypothesis is that this N-PTH molecule 
has 84 amino acids, but its serine residue 17 may be 
phosphorylated, which modifies the binding site of 
the amino-terminal antibody used in the I-PTH assay 
(10). This situation is more likely to be found in severe 
hyperparathyroidism and parathyroid carcinomas, 
although it has already been described in seven patients 
with primary hyperparathyroidism without any clinical 
or histological signs of parathyroid carcinoma (14). 
In our cohort with primary hyperparathyroidism, one 
patient showed a higher PTH value using the Bio-PTH 
assay compared with the I-PTH.
In our cohort with primary hyperparathyroidism, 
the I-PTH and Bio-PTH assays identified elevated PTH 
levels in 87.8% and 92.7% of the patients, respectively. 
Aligned with findings by other authors, we found a high 
correlation between the two methods in these patients 
(23-25). However, the Passing-Bablok and Bland-
Altman tests showed a proportional and systematic 
difference between both methods, indicating that the 
second and third-generation PTH assays may not be 
used interchangeably.
In the literature, there are only a few studies 
evaluating third-generation PTH assays in patients with 
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primary hyperparathyroidism (8,23-25). Silverberg and 
cols. have found significantly higher sensitivity with 
third-generation assays in a population with primary 
hyperparathyroidism (8). The explanation for this 
superior diagnostic specificity may be related to the use 
of different control groups to define the normal PTH 
values for each assay, especially regarding potential 
differences in vitamin D status in these populations 
(8,14,25). Populations with different vitamin D levels 
may have been used to establish the normal range for 
each assay (14). Also, many other factors may interfere 
with PTH values in addition to vitamin D status, 
including calcium and magnesium intake, gender, age, 
and ethnicity (14,26). Although we used two different 
populations in our study to estimate the normal 
range for each assay, all controls had 25(OH)D levels 
greater than 25 ng/mL. This may explain the absence 
of differences in diagnostic sensitivity between both 
assays, which is consistent with findings also reported 
by several other authors (23-25). 
One remarkable finding in our patients with 
primary hyperparathyroidism was their low levels of 
25(OH)D (mean 16 ng/mL). Patients with primary 
hyperparathyroidism have been described as having 
vitamin D deficiency when compared with individuals 
in the normal population (27). The mechanisms 
behind this finding are not well understood, but 
one of the factors involved may be a greater PTH 
conversion of 25(OH)D to 1,25-dihydroxyvitamin D 
[1,25(OH)2D]. Furthermore, the subsequent increase 
in 1,25(OH)2D levels stimulate the inactivation of 
25(OH)D by 24-hydroxylases (27).
In conclusion, serum PTH results correlated 
well when measured with a third-generation assay 
(Bio-PTH) and a second-generation assay (I-PTH). 
We found that the use of a third-generation assay 
was not superior to that of a second-generation assay 
in the diagnosis of primary hyperparathyroidism. 
Nevertheless, the assays are different and should not be 
used interchangeably. Although we evaluated patients 
with primary hyperparathyroidism with an indication 
for surgery and high levels of serum calcium, this assay 
could be potentially helpful also in suspicious cases of 
primary hyperparathyroidism with borderline PTH 
values and mild disease. Another aspect to be explored 
in relation to the assays is their intraoperative use. Since 
the half-life of PTH 1–84 is slightly shorter than that 
of PTH fragments, the assays may help identify an early 
decrease in PTH levels (4). 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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